Skip to main content
ZNTL
NASDAQ Life Sciences

Zentalis Prices 23M Share Offering at $3.50, Raising $75.1M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$3.54
Mkt Cap
$255.152M
52W Low
$1.212
52W High
$6.95
52W Position info
192% above low
Off High info
49% below high
Rel. Volume info
3.8× avg
Market data snapshot near publication time

ZNTL has more than doubled off its 52-week low of $1.212 on elevated volume (3.8× avg).

Summary

Zentalis priced a 23 million share offering at $3.50 per share, raising $75.1 million to fund its ovarian cancer drug development through early 2028.


Key Events · Financing and Capital Events · ZNTL

  • Offering Priced at $3.50

    23,000,000 shares offered at $3.50 per share, a 6.6% discount to the August 13 close of $4.15, raising $80.5M gross.

  • Net Proceeds $75.1M

    After $4.83M underwriting discount and $600K expenses, net proceeds are $75.1M; option for 3.45M more shares could add $11.3M.

  • Dilution of 32%

    Shares outstanding increase from 71.7M to 94.7M (32% dilution); net tangible book value per share rises from $2.00 to $2.31, diluting new investors by $1.19 per share.

  • Runway Extended to 1H 2028

    Proceeds fund clinical trials, manufacturing, and pre-commercial activities, extending cash runway into the first half of 2028.


Analysis · ZNTL · Life Sciences

Zentalis finalized a 23 million share public offering at $3.50 per share, a 6.6% discount to the prior close, raising approximately $75.1 million in net proceeds. The offering increases shares outstanding by about 32% and dilutes new investors by $1.19 per share. Proceeds extend the cash runway into the first half of 2028, funding the pivotal DENALI Part 2 and ASPENOVA trials for azenosertib. The underwriters have a 30-day option for 3.45 million additional shares, which could raise total net proceeds to $86.4 million.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ZNTL was trading at $3.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $255.2M. The 52-week trading range was $1.21 to $6.95. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ZNTL - Latest Insights

ZNTL
Nov 09, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.74
Real-time Price: $1.60 info
Change: -$0.140 (-8%) info
Market Cap: $157.225M info
ZNTL
Oct 23, 2026, 10:15 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.31
Real-time Price: $1.60 info
Change: -$0.710 (-31%) info
Market Cap: $157.225M info
ZNTL
Oct 19, 2026, 2:31 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $2.29
Real-time Price: $1.60 info
Change: -$0.685 (-30%) info
Market Cap: $157.225M info
ZNTL
Oct 18, 2026, 6:11 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $2.11
Real-time Price: $1.60 info
Change: -$0.510 (-24%) info
Market Cap: $157.225M info
ZNTL
Aug 19, 2026, 6:11 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $3.82
Real-time Price: $1.60 info
Change: -$2.22 (-58%) info
Market Cap: $157.225M info